ALKS

ALKS

USD

Alkermes plc Ordinary Shares

$30.480+0.480 (1.600%)

Prix en Temps Réel

Healthcare
Drug Manufacturers - Specialty & Generic
Irlande

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$30.000

Haut

$30.630

Bas

$29.770

Volume

0.42M

Fondamentaux de l'Entreprise

Capitalisation Boursière

5.0B

Industrie

Drug Manufacturers - Specialty & Generic

Pays

Ireland

Statistiques de Trading

Volume Moyen

2.00M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $25.17Actuel $30.480Haut $36.45

Actualités Connexes

Analyst Upgrades

Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42

Wells Fargo analyst Benjamin Burnett maintains Alkermes with a Overweight and lowers the price target from $44 to $42.

Voir plus
Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42
Analyst Upgrades

Needham Maintains Buy on Alkermes, Raises Price Target to $44

Needham analyst Ami Fadia maintains Alkermes with a Buy and raises the price target from $43 to $44.

Voir plus
Needham Maintains Buy on Alkermes, Raises Price Target to $44
PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving ...

Voir plus
Alkermes plc Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45

Mizuho analyst Uy Ear maintains Alkermes with a Outperform and raises the price target from $40 to $45.

Voir plus
Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45
Analyst Upgrades

Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45

Piper Sandler analyst David Amsellem reiterates Alkermes with a Overweight and raises the price target from $38 to $45.

Voir plus
Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45
Analyst Upgrades

RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $47

RBC Capital analyst Leonid Timashev maintains Alkermes with a Outperform and raises the price target from $45 to $47.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.